$CRNX
Crinetics Pharmaceuticals, Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024057150 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $399.0K $640.0K $2.679M
YoY Change -59.62% -76.11% -14.44%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $24.84M $20.83M $12.19M
YoY Change 86.15% 70.88% 40.01%
% of Gross Profit
Research & Development $58.34M $53.34M $38.47M
YoY Change 43.56% 38.66% 36.16%
% of Gross Profit
Depreciation & Amortization $753.0K $474.0K $283.0K
YoY Change 168.93% 67.49% 17.92%
% of Gross Profit
Operating Expenses $83.18M $74.17M $50.66M
YoY Change 54.09% 46.41% 37.07%
Operating Profit -$82.78M -$73.53M -$47.98M
YoY Change 56.21% 53.26% 41.83%
Interest Expense $8.775M $7.320M $1.983M
YoY Change -325.4% 269.14% 844.29%
% of Operating Profit
Other Income/Expense, Net $8.728M $7.069M $1.983M
YoY Change 332.94% 256.48% 844.29%
Pretax Income -$74.06M -$66.46M -$46.00M
YoY Change 45.27% 44.49% 36.82%
Income Tax
% Of Pretax Income
Net Earnings -$74.06M -$66.93M -$46.00M
YoY Change 45.27% 45.52% 32.83%
Net Earnings / Revenue -18560.15% -10457.81% -1716.87%
Basic Earnings Per Share -$0.94 -$0.93 -$0.85
Diluted Earnings Per Share -$0.94 -$0.93 -$0.85
COMMON SHARES
Basic Shares Outstanding 78.86M 69.60M 53.91M
Diluted Shares Outstanding 79.01M 72.29M 53.91M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $653.0M $601.2M $250.2M
YoY Change 214.85% 140.23% -21.73%
Cash & Equivalents $302.2M $395.9M $41.19M
Short-Term Investments $350.8M $205.2M $209.1M
Other Short-Term Assets $1.512M $3.556M $3.287M
YoY Change -45.24% 8.18% 103.28%
Inventory
Prepaid Expenses
Receivables
Other Receivables $119.0K $114.0K
Total Short-Term Assets $874.8M $917.2M $305.4M
YoY Change 207.14% 200.33% -6.96%
LONG-TERM ASSETS
Property, Plant & Equipment $12.25M $11.87M $3.266M
YoY Change 279.99% 263.29% 22.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change
Other Assets $2.202M $2.000M $2.000M
YoY Change 10.1% 0.0% 252.11%
Total Long-Term Assets $60.76M $60.93M $8.606M
YoY Change 619.55% 607.94% 70.86%
TOTAL ASSETS
Total Short-Term Assets $874.8M $917.2M $305.4M
Total Long-Term Assets $60.76M $60.93M $8.606M
Total Assets $935.5M $978.2M $314.0M
YoY Change 219.02% 211.5% -5.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.872M $10.76M $5.895M
YoY Change 83.12% 82.46% -51.42%
Accrued Expenses $42.95M $38.55M $18.31M
YoY Change 67.2% 110.59% 237.92%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $54.38M $51.77M $26.32M
YoY Change 66.75% 96.68% 29.94%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $202.0K $51.45M $7.358M
YoY Change -96.91% 599.28% -26.31%
Total Long-Term Liabilities $202.0K $51.45M $7.358M
YoY Change -96.91% 599.28% -26.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $54.38M $51.77M $26.32M
Total Long-Term Liabilities $202.0K $51.45M $7.358M
Total Liabilities $104.8M $103.2M $33.68M
YoY Change 167.7% 206.48% 11.36%
SHAREHOLDERS EQUITY
Retained Earnings -$794.7M -$720.6M -$485.2M
YoY Change 48.24% 48.52% 56.57%
Common Stock $881.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $830.8M $874.9M $280.3M
YoY Change
Total Liabilities & Shareholders Equity $935.5M $978.2M $314.0M
YoY Change 219.02% 211.5% -5.78%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$74.06M -$66.93M -$46.00M
YoY Change 45.27% 45.52% 32.83%
Depreciation, Depletion And Amortization $753.0K $474.0K $283.0K
YoY Change 168.93% 67.49% 17.92%
Cash From Operating Activities -$45.62M -$52.86M -$40.72M
YoY Change -0.26% 29.81% 200.66%
INVESTING ACTIVITIES
Capital Expenditures $955.0K $1.332M $16.00K
YoY Change 302.95% 8225.0% -81.61%
Acquisitions
YoY Change
Other Investing Activities -$52.69M $1.641M $48.77M
YoY Change -266.34% -96.64% -212.64%
Cash From Investing Activities -$53.64M $309.0K $48.76M
YoY Change -270.64% -99.37% -212.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $350.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.496M 393.6M 484.0K
YoY Change -56.58% 81216.94% -72.81%
NET CHANGE
Cash From Operating Activities -45.62M -52.86M -40.72M
Cash From Investing Activities -53.64M 309.0K 48.76M
Cash From Financing Activities 5.496M 393.6M 484.0K
Net Change In Cash -93.76M 341.0M 8.521M
YoY Change 5613.71% 3902.19% -115.45%
FREE CASH FLOW
Cash From Operating Activities -$45.62M -$52.86M -$40.72M
Capital Expenditures $955.0K $1.332M $16.00K
Free Cash Flow -$46.57M -$54.19M -$40.73M
YoY Change 1.31% 33.03% 198.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001658247
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-38583
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Crinetics Pharmaceuticals, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3744114
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
6055 Lusk Boulevard
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2024Q1 dei City Area Code
CityAreaCode
858
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
450-6464
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
CRNX
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
78859510
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
395924000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54897000
CY2024Q1 us-gaap Short Term Investments
ShortTermInvestments
505037000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
503658000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16267000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15598000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
917228000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
574153000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11865000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10881000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
45760000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
46549000
CY2024Q1 crnx Investment In Radionetics
InvestmentInRadionetics
0
CY2023Q4 crnx Investment In Radionetics
InvestmentInRadionetics
470000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1300000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1300000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2000000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2000000
CY2024Q1 us-gaap Assets
Assets
978153000
CY2023Q4 us-gaap Assets
Assets
635353000
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
28683000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
23196000
CY2024Q1 crnx Accrued Compensation And Related Expense
AccruedCompensationAndRelatedExpense
14829000
CY2023Q4 crnx Accrued Compensation And Related Expense
AccruedCompensationAndRelatedExpense
14517000
CY2024Q1 us-gaap Deferred Revenue
DeferredRevenue
2463000
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
2056000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5792000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4173000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
51767000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
43942000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
46712000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47555000
CY2024Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4741000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4750000
CY2024Q1 us-gaap Liabilities
Liabilities
103220000
CY2023Q4 us-gaap Liabilities
Liabilities
96247000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78539000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78539000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68175000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68175000
CY2024Q1 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
1595415000
CY2023Q4 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
1191831000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
150000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
977000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-720632000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-653702000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
874933000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
539106000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
978153000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
635353000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
640000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2679000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53341000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38468000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20828000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12189000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
74169000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
50657000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-73529000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-47978000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
7320000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2038000
CY2024Q1 crnx Other Income Expense
OtherIncomeExpense
-251000
CY2023Q1 crnx Other Income Expense
OtherIncomeExpense
-55000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7069000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1983000
CY2024Q1 crnx Loss Before Equity Method Investment
LossBeforeEquityMethodInvestment
66460000
CY2023Q1 crnx Loss Before Equity Method Investment
LossBeforeEquityMethodInvestment
45995000
CY2024Q1 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
-470000
CY2023Q1 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
0
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-66930000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-45995000
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72289000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72289000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53908000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53908000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-827000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1417000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-67757000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44578000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
539106000
CY2024Q1 crnx Transaction Cost On Issuance Of Common Stock
TransactionCostOnIssuanceOfCommonStock
15810000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
378890000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11240000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13454000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-827000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-66930000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
874933000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
316328000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
484000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8096000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1417000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-45995000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
280330000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-66930000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-45995000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
13454000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
8096000
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
474000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
283000
CY2024Q1 crnx Non Cash Lease Expense
NonCashLeaseExpense
789000
CY2023Q1 crnx Non Cash Lease Expense
NonCashLeaseExpense
115000
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3847000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
530000
CY2024Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-42000
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2024Q1 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
-470000
CY2023Q1 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
0
CY2024Q1 crnx Noncash License Revenues
NoncashLicenseRevenues
0
CY2023Q1 crnx Noncash License Revenues
NoncashLicenseRevenues
2000000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-212000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1516000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1306000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1345000
CY2024Q1 us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
-398000
CY2023Q1 us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
605000
CY2024Q1 crnx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
776000
CY2023Q1 crnx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-253000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52856000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40718000
CY2024Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
99741000
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
22671000
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
101382000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
71442000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1332000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
309000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
48755000
CY2024Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
15810000
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
15810000
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
383215000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10359000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
484000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
393574000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
484000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
341027000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8521000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56197000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33973000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
397224000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42494000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
395924000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41193000
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
1300000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
1301000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
397224000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42494000
CY2024Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
4325000
CY2023Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
CY2024Q1 crnx Options Exercise Receivable
OptionsExerciseReceivable
881000
CY2023Q1 crnx Options Exercise Receivable
OptionsExerciseReceivable
0
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
168000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
33000
CY2024Q1 crnx Private Company Shares Received Under Licensing Arrangements
PrivateCompanySharesReceivedUnderLicensingArrangements
0
CY2023Q1 crnx Private Company Shares Received Under Licensing Arrangements
PrivateCompanySharesReceivedUnderLicensingArrangements
2000000
CY2024Q1 crnx Available For Sale Investment Securities Less Than12 Months Fair Market Value
AvailableForSaleInvestmentSecuritiesLessThan12MonthsFairMarketValue
186117000
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-720600000
CY2024Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
901000000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
89252000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
504886000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
505037000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
502681000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
503658000
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16227000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12619000
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
504886000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
394000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
243000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
505037000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
502681000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1275000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
298000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
503658000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
458986000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
459136000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
414031000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
414406000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
45900000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
45901000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
88650000
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
189000
CY2024Q1 crnx Available For Sale Investment Securities More Than12 Months Fair Value
AvailableForSaleInvestmentSecuritiesMoreThan12MonthsFairValue
19128000
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
54000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
205245000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
243000
CY2023Q4 crnx Available For Sale Investment Securities Less Than12 Months Fair Market Value
AvailableForSaleInvestmentSecuritiesLessThan12MonthsFairMarketValue
22409000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
15000
CY2023Q4 crnx Available For Sale Investment Securities More Than12 Months Fair Value
AvailableForSaleInvestmentSecuritiesMoreThan12MonthsFairValue
51683000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
283000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
74092000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
298000
CY2024Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2024Q1 crnx Prepaid Clinical Costs
PrepaidClinicalCosts
2358000
CY2023Q4 crnx Prepaid Clinical Costs
PrepaidClinicalCosts
2574000
CY2024Q1 crnx Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
444000
CY2023Q4 crnx Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
1238000
CY2024Q1 crnx Foreign Tax Incentive Receivable Current
ForeignTaxIncentiveReceivableCurrent
711000
CY2023Q4 crnx Foreign Tax Incentive Receivable Current
ForeignTaxIncentiveReceivableCurrent
747000
CY2024Q1 us-gaap Prepaid Insurance
PrepaidInsurance
469000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
857000
CY2024Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
3173000
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
3051000
CY2024Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
114000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
90000
CY2024Q1 crnx Landlord Improvements Receivable
LandlordImprovementsReceivable
4561000
CY2023Q4 crnx Landlord Improvements Receivable
LandlordImprovementsReceivable
5210000
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
881000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
253000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
3556000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1578000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16267000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15598000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17343000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15949000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5478000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5068000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11865000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10881000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
10756000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6548000
CY2024Q1 crnx Accrued Clinical Costs
AccruedClinicalCosts
5717000
CY2023Q4 crnx Accrued Clinical Costs
AccruedClinicalCosts
5527000
CY2024Q1 crnx Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
4245000
CY2023Q4 crnx Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
2312000
CY2024Q1 crnx Accrued Outside Services And Professional Fees
AccruedOutsideServicesAndProfessionalFees
4550000
CY2023Q4 crnx Accrued Outside Services And Professional Fees
AccruedOutsideServicesAndProfessionalFees
1726000
CY2024Q1 crnx Accrued Landlord Improvements2
AccruedLandlordImprovements2
2926000
CY2023Q4 crnx Accrued Landlord Improvements2
AccruedLandlordImprovements2
3816000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
489000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3267000
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
28683000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
23196000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4173000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7468000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6795000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6999000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
7209000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
50975000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
83619000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
31115000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
52504000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5792000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
46712000
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2000000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
300000
CY2024Q1 crnx Upfront Payment As License Revenue
UpfrontPaymentAsLicenseRevenue
600000
CY2023Q1 crnx Upfront Payment As License Revenue
UpfrontPaymentAsLicenseRevenue
600000
CY2024Q1 crnx Upfront Payment As Deferred Revenue
UpfrontPaymentAsDeferredRevenue
14000000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12627124
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.96
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2518953
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
43.06
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
605083
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
18.57
CY2024Q1 crnx Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited And Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndExpired
84255
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
19.31
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14456739
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.17
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
341736000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
14456739
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
23.17
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
341736000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5376802
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
17.39
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M6D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
158183000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
13800000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.67
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.67
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.042
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.042
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0
CY2023Q1 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13454000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8096000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32344371
CY2023Q3 crnx Additional Sales Milestones
AdditionalSalesMilestones
15000000
CY2024Q1 crnx Due From Radionetics Current
DueFromRadioneticsCurrent
100000
CY2023Q4 crnx Due From Radionetics Current
DueFromRadioneticsCurrent
100000
CY2024Q1 crnx Reimbursement Earned
ReimbursementEarned
31000
CY2023Q1 crnx Reimbursement Earned
ReimbursementEarned
13000
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0000950170-24-057150-index-headers.html Edgar Link pending
0000950170-24-057150-index.html Edgar Link pending
0000950170-24-057150.txt Edgar Link pending
0000950170-24-057150-xbrl.zip Edgar Link pending
crnx-20240331.htm Edgar Link pending
crnx-20240331.xsd Edgar Link pending
crnx-ex10_1.htm Edgar Link pending
crnx-ex31_1.htm Edgar Link pending
crnx-ex31_2.htm Edgar Link pending
crnx-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
crnx-20240331_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending